The Effect and Safety of 5-HT_1F Receptor Agonist Lasmiditan on Migraine: A Systematic Review and Meta-Analysis.

ABSTRACT:

Background

Migraine has a great impact on public health. Current acute therapies do not satisfy all migraineurs. The novel serotonin 5-HT_1F receptor agonist appears more promising for aborting migraine attacks.

Objective

To evaluate the clinical efficacy and safety of lasmiditan in treating acute migraine attacks.

Methods

The literature search was performed in PubMed, Embase, and the Cochrane Central Register of Controlled Trials for randomized controlled trials (RCTs) which assessed the effect and safety of lasmiditan on migraine. The risk of bias was assessed using the Cochrane Collaboration's risk of bias tool. Results were extracted and pooled as risk ratios (RRs) with a fixed or random-effects model.

Results

Based on the four included RCTs, pool

SUBMITTER: Gu P 

PROVIDER: S-EPMC8517628 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature